Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artesunate + mefloquine
- Development stage
- Phase 4
- Lead developer
- Drugs for Neglected Diseases initiative
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Artesunate + mefloquine** is an oral fixed-dose artemisinin-based combination therapy for acute uncomplicated *Plasmodium falciparum* malaria, including some mixed *Plasmodium* infections. It combines artesunate, a rapidly acting artemisinin derivative, with the longer-acting quinoline antimalarial mefloquine to clear residual blood-stage parasites after the initial rapid parasite reduction. The ASMQ fixed-dose product was developed to simplify three-day treatment, support adherence, and reduce the risk of functional monotherapy. Fixed-dose ASMQ products have been developed and registered or supplied in multiple endemic settings, including paediatric tablet and granule formulations. ([dndi.org](https://dndi.org/research-development/portfolio/asmq))
- Brand names
- ArtequinArtequin PaediatricFalcigo PlusFalcigo Plus JuniorFarmanguinhos Artesunato + Mefloquina
- Other names
- AS-MQASMQMAMAS3MAS-3MAS 3MQ-ASMQASartesunate-mefloquineartesunate/mefloquinemefloquine + artesunatemefloquine-artesunate
02
Targets
PfHRP2 (Plasmodium falciparum histidine-rich protein II)PfACBP (Plasmodium falciparum acyl-CoA-binding protein)
Beyond the preview
Go deeper on artesunate + mefloquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artesunate + mefloquine.